GLUE vs NRIX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GLUE and NRIX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GLUE and NRIX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Monte Rosa Therapeutics develops molecular glue degraders (MGDs), small molecules that recruit the cell's natural ubiquitin-proteasome system to selectively eliminate target proteins that are otherwise hard to drug. Its QuEEN discovery engine pairs AI-guided chemistry with structural biology and proteomics to design these degraders. The pipeline centers on three programs: MRT-6160 (a VAV1-directed degrader for immune-mediated diseases, licensed to Novartis), MRT-8102 (a NEK7/NLRP3-pathway degrader for inflammatory and cardiovascular disease that posted positive interim Phase 1 data in January 2026), and MRT-2359 (a MYC-pathway degrader in oncology).

Full GLUE guide

Nurix Therapeutics is a clinical-stage biopharmaceutical company that designs targeted protein degradation medicines, small molecules that harness the body's own protein-disposal machinery to eliminate disease-driving proteins rather than merely blocking them. Its lead program, bexobrutideg (NX-5948), is an oral, brain-penetrant degrader of BTK being studied in chronic lymphocytic leukemia and other blood cancers, with a pivotal Phase 2 DAYBreak CLL-201 study supporting a potential accelerated approval and a Phase 3 DAYBreak CLL-306 study planned to begin around mid-2026. Beyond bexobrutideg, Nurix has wholly owned programs including zelebrudomide (NX-2127) and the CBL-B inhibitor NX-1607, plus partnered discovery work with Gilead Sciences, Sanofi, and Pfizer where it retains options to co-develop and share profits.

Full NRIX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GLUE drivers: Novartis partnerships; MRT-8102 in inflammation and cardiovascular disease.
• NRIX drivers: Bexobrutideg pivotal path; Roche collaboration.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Monte Rosa is pre-product and unprofitable, so it depends on clinical success and continued financing. For NRIX, as a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so it posts substantial net losses and depends on its cash balance and partner payments to keep funding trials.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GLUE if you believe its drivers more; NRIX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GLUE and NRIX guides.

GLUE. Revenue is collaboration and license income (largely Novartis-related), not product sales, and it varies with deal timing. Standard valuation multiples like P/E do not apply to a pre-profit biotech; the market is pricing platform potential and milestone optionality. The large cash balance funds operations into 2029 without immediate financing pressure.

NRIX. Nurix is pre-profit, so traditional metrics like P/E do not apply; the market values it on pipeline potential, partnership economics, and cash runway. Q1 FY2026 revenue fell sharply year over year as certain Sanofi collaboration research terms wound down, while R&D spending drove a wider net loss. The roughly $540 million cash position funds the registrational bexobrutideg program and broader pipeline, though a quarterly burn near $80 million and future trials mean funding and dilution remain key watch items.

Headline figures (approximate, JULY 2026): GLUE shows market cap ~$2.05B, share price ~$24, revenue (ttm) ~$43M, net loss (ttm) ~-$130M; NRIX shows revenue (q1 fy2026, quarter ended feb 28 2026) ~$6.3 million, revenue (year-ago quarter) ~$18.5 million, r&d expense (q1 fy2026) ~$84.1 million, net loss (q1 fy2026) ~$87.2 million (~-$0.79 per share).

GLUE and NRIX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GLUE and NRIX exposure against your real portfolio. It is not an investment adviser.